• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    New developments in the treatment of postmenopausal breast cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Howell, Anthony
    Affiliation
    CRUK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. maria.parker@christie-tr.nwest.nhs.uk
    Issue Date
    2005-11
    
    Metadata
    Show full item record
    Abstract
    In recent years, new agents have challenged tamoxifen as the standard endocrine therapy for postmenopausal breast cancer. This article reviews developments with regard to the third-generation aromatase inhibitors (AIs)--anastrozole, letrozole and exemestane--and fulvestrant, the first of a new type of estrogen receptor antagonist that, unlike tamoxifen, has no partial agonist activity. The final results of the "Arimidex", Tamoxifen, Alone or in Combination (ATAC) trial, at a median follow-up of more than five years, and recent results from switching studies with anastrozole and exemestane, strengthen the position of these AIs as adjuvant treatment for hormone receptor-positive early breast cancer. Sequencing options for the future are also discussed because non-steroidal AIs are increasingly used early in the treatment sequence.
    Citation
    New developments in the treatment of postmenopausal breast cancer. 2005, 16 (9):420-8 Trends Endocrinol. Metab.
    Journal
    Trends in Endocrinology and Metabolism
    URI
    http://hdl.handle.net/10541/74875
    DOI
    10.1016/j.tem.2005.09.003
    PubMed ID
    16213745
    Type
    Article
    Language
    en
    ISSN
    1043-2760
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.tem.2005.09.003
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    • Authors: Buzdar AU, Cuzick J
    • Issue date: 2006 Feb 1
    • The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    • Authors: Mouridsen HT, Robert NJ
    • Issue date: 2005 Aug
    • Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
    • Authors: Ingle JN
    • Issue date: 2006 Feb 1
    • Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    • Authors: Berry J
    • Issue date: 2005 Nov
    • Focus on anastrozole and breast cancer.
    • Authors: Mokbel K
    • Issue date: 2003
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.